- Lilly reports full Q4 2024 financial results and provides 2025 guidance
For Q4 2024, worldwide Mounjaro revenue increased 60% to $3 53 billion U S revenue was $2 63 billion, an increase of 25%, reflecting continued strong demand and increased supply, partially offset by lower realized prices due to favorable changes in Q4 2023 to estimates for rebates and discounts
- Investors | Eli Lilly and Company
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts
- Lilly reports first-quarter 2025 financial results and highlights . . .
INDIANAPOLIS, May 1, 2025 PRNewswire -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025 "Lilly had a solid start to the year, with 45% year-over-year revenue growth driven by strong sales of Mounjaro and Zepbound," said David A Ricks, Lilly chair and CEO
- Lilly provides update on 2024 revenue guidance, announces 2025 revenue . . .
The company also shared 2025 revenue guidance, anticipating sales will be between $58 0 billion and $61 0 billion For Q4 2024, Lilly now expects worldwide revenue to be approximately $13 5 billion, representing growth of 45% compared to Q4 2023 This includes approximately $3 5 billion for Mounjaro ® and $1 9 billion for Zepbound ®
- Presentation - Eli Lilly and Company
Deliver Revenue Growth Revenue grew 26% in Q1 driven by Mounjaro®, Zepbound®, Verzenio®, and Jardiance®1 New Product2 revenue grew by $1 79 billion to $2 39 billion in Q1
- Q1 2025 EARNINGS CALL - investor. lilly. com
Reaffirmed 2025 Revenue Guidance of $58 0B to $61 0B Therapeutics’ mutant selective PI3Kα inhibitor program consistent with injectable GLP-1 medicines 1 Key products include Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio and Zepbound Note: Revenue growth rates reflect change vs Q1 2024
- Lilly provides update on 2024 revenue guidance, announces 2025 revenue . . .
The company also shared 2025 revenue guidance, anticipating sales will be between $58 0 billion and $61 0 billion For Q4 2024, Lilly now expects worldwide revenue to be approximately $13 5 billion, representing growth of 45% compared to Q4 2023 This includes approximately $3 5 billion for Mounjaro® and $1 9 billion for Zepbound®
- Presentation - Eli Lilly and Company
Deliver Revenue Growth Revenue grew 36% in Q2 driven by Mounjaro®, Zepbound®, and Verzenio®; New Product1revenue grew nearly $3 5 billion Excluding the sale of rights to Baqsimi®, non-incretin revenue growth was 17% worldwide, with 25% revenue growth in the U S
|